EL.PA
EssilorLuxottica S.A.
Healthcare · Medical - Instruments & Supplies
Undervalued·RSI 27·DCF +39%·Conviction 70
Investment Thesis — EssilorLuxottica S.A.
The market is myopically fixated on recent cyclical deceleration in North America and perceived competitive threats, failing to appreciate EssilorLuxottica's unparalleled structural advantages: its essential healthcare utility, deep innovation pipeline, and formidable global distribution network. This creates a compelling entry point for a durable compounder.
Catalysts
- Strong Q3/Q4 2024 results showing stabilization or reacceleration of North American sales.
- Successful launch and widespread adoption of new smart eyewear products (e.g., Ray-Ban Meta updates, new tech).
- Resolution of regulatory uncertainties or clear communication on future strategy regarding market integration.
Risk Factors
- Increased regulatory scrutiny or anti-trust action, particularly in Europe or the US, impacting its integrated model.
- Sustained weakness in consumer spending, especially in luxury segments, impacting premium eyewear sales.
- Rapid market share erosion from direct-to-consumer (DTC) competitors or unbranded alternatives, forcing price concessions.
Key Debates
Fwd Revenue Growth exceeds 11.5% by H1 2025 on emerging market expansion
Operating leverage boosts Fwd P/E to 28x by Q4 2024
Fwd P/E rerates to 23x by Q3 2024 on interest rate pressures